Search results
Results From The WOW.Com Content Network
Bayer AG ( English: / ˈbaɪ.ər /, commonly pronounced / ˈbeɪər /; [3] German: [ˈbaɪɐ]) is a German multinational pharmaceutical and biotechnology company and is one of the largest pharmaceutical companies and biomedical companies in the world. Headquartered in Leverkusen, Bayer's areas of business include: pharmaceuticals, consumer ...
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers ...
AstraZeneca plc ( / ˌæstrəˈzɛnəkə /) ( AZ) is a British-Swedish multinational pharmaceutical and biotechnology company [2] [3] [4] with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. [5] It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection ...
Sanofi-Aventis (SNY) shares are up nearly 2% in early morning trading after it announced it entered into a global, strategic alliance with Regulus Therapeutics to discover, develop, and ...
Stellantis Gurun Plant. Stellantis Gurun (Malaysia) Sdn Bhd (formerly Naza Automotive Manufacturing Sdn Bhd, abbreviated NAM) is an automotive manufacturing subsidiary of Stellantis in Malaysia. It is headquartered in Gurun, Kedah . The company was established in 2002 and by 2003, the construction of NAM's own manufacturing plant commenced.
French pharmaceutical company Sanofi-Aventis (SNY), which has been unsuccessful in its recent courtship of U.S. biotech giant Genzyme (GENZ), announced Thursday it signed a 10-year agreement with ...
Paris-based pharmaceutical Sanofi-Aventis (SNY) has extended the deadline for its tender offer for Cambridge, Mass.-based biotech Genzyme (GENZ) by six weeks, from Dec. 10 to Jan. 21, 2011. All ...
On March 9, 2010, Sanofi-Aventis announced it had exercised an option to combine Merial with Intervet/Schering Plough, the animal health business of Merck. The new joint venture would be equally owned by Merck and Sanofi-Aventis. On March 22, 2011, they announced the mutual termination of their agreement to form a new animal health joint venture.